Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions

GLIA

Volumn 59, Issue 2, 2011, Pages 188-199

  Drouin Ouellet, Janelle ^a   Brownell, Anna Liisa ^b   Saint Pierre, Martine ^a   Fasano, Caroline ^c   Emond, Vincent ^a   Trudeau, Louis Eric ^c   Lévesque, Daniel ^c   Cicchetti, Francesca ^a,d  

^a LAVAL UNIVERSITY   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

Activated microglia; Astrocytes; Metabotropic glutamate receptor type 5 (mGluR5), ibotenic acid; Minocycline; Neonatal ventral hippocampal lesion

Indexed keywords

IBOTENIC ACID; METABOTROPIC RECEPTOR 5; MINOCYCLINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN DAMAGE; BRAIN DEVELOPMENT; CELL ACTIVATION; CONTROLLED STUDY; EXCITOTOXICITY; GLIA CELL; HIPPOCAMPUS; MALE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AMPHETAMINE; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS; BEHAVIOR, ANIMAL; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HIPPOCAMPUS; IBOTENIC ACID; INTERPERSONAL RELATIONS; ISOQUINOLINES; MALE; MAZE LEARNING; MICROTUBULE-ASSOCIATED PROTEINS; MINOCYCLINE; MOTOR ACTIVITY; NEUROGLIA; NEURONS; NEUROTOXICITY SYNDROMES; PHOSPHOPYRUVATE HYDRATASE; POSITRON-EMISSION TOMOGRAPHY; PREGNANCY; RADIOLIGAND ASSAY; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; TRITIUM;

EID: 78650236263     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.21086     Document Type: Article

References (49)

1. Abe T, Sugihara H, Nawa H, Shigemoto R, Mizuno N, Nakanishi S. 1992. Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J Biol Chem 267: 13361-13368.
2. Aronica E, Catania MV, Geurts J, Yankaya B, Troost D. 2001. Immunohistochemical localization of group I, II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: Upregulation in reactive astrocytes. Neuroscience 105: 509-520.
3. Aronica E, van Vliet EA, Mayboroda OA, Troost D, da Silva FH, Gorter JA. 2000. Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. Eur J Neurosci 12: 2333-2344.
4. Barrington KJ. 2001. Postnatal steroids and neurodevelopmental outcomes: a problem in the making. Pediatrics 107: 1425-1426.
5. Berger A. 2000. Minocycline slows progress of Huntington's disease in mice. BMJ 321: 70.
6. Biber K, Laurie DJ, Berthele A, Sommer B, Tolle TR, Gebicke-Harter PJ, van Calker D, Boddeke HW. 1999. Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J Neurochem 72: 1671-1680.
7. Borrell J, Vela JM, Arevalo-Martin A, Molina-Holgado E, Guaza C. 2002. Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology 26: 204-215.
8. Byrnes KR, Stoica B, Loane DJ, Riccio A, Davis MI, Faden AI. 2009a. Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity. Glia 57: 550-560.
9. Byrnes KR, Stoica B, Riccio A, Pajoohesh-Ganji A, Loane DJ, Faden AI. 2009b. Activation of metabotropic glutamate receptor 5 improves recovery after spinal cord injury in rodents. Ann Neurol 66: 63-74.
10. Cai Z, Lin S, Fan LW, Pang Y, Rhodes PG. 2006. Minocycline alleviates hypoxic-ischemic injury to developing oligodendrocytes in the neonatal rat brain. Neuroscience 137: 425-435.
11. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, et al. 2000. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6: 797-801.
12. Cicchetti F, Saporta S, Hauser RA, Parent M, Saint-Pierre M, Sanberg PR, Li XJ, Parker JR, Chu Y, Mufson EJ, et al. 2009. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci USA 106: 12483-12488.
13. Conn PJ, Lindsley CW, Jones CK. 2009. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 30: 25-31.
14. Conover WJ. 1999. Practical Nonparametric Statistics. New York: Wiley. 592 p.
15. Cunningham C, Campion S, Teeling J, Felton L, Perry VH. 2007. The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I:C). Brain Behav Immun 21: 490-502.
16. Deacon RM, Rawlins JN. 2006. T-maze alternation in the rodent. Nat Protoc 1: 7-12.
17. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, et al. 2001. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98: 14669-14674.
18. Fan LW, Pang Y, Lin S, Rhodes PG, Cai Z. 2005a. Minocycline attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neuroscience 133: 159-168.
19. Fan LW, Pang Y, Lin S, Tien LT, Ma T, Rhodes PG, Cai Z. 2005b. Minocycline reduces lipopolysaccharide-induced neurological dysfunction and brain injury in the neonatal rat. J Neurosci Res 82: 71-82.
20. Fasano C, Thibault D, Trudeau LE. 2008. Culture of postnatal mesencephalic dopamine neurons on an astrocyte monolayer. Curr Protoc Neurosci 3: 21.
21. Geurts JJ, Wolswijk G, Bo L, van der Valk P, Polman CH, Troost D, Aronica E. 2003. Altered expression patterns of group I, II metabotropic glutamate receptors in multiple sclerosis. Brain 126(Part 8): 1755-1766.
22. Gibrat C, Saint-Pierre M, Bousquet M, Levesque D, Rouillard C, Cicchetti F. 2009. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J Neurochem 109: 1469-1482.
23. Glaser JR, Glaser EM. 2000. Stereology, morphometry, and mapping: The whole is greater than the sum of its parts. J Chem Neuroanat 20: 115-126.
24. Julien C, Tremblay C, Emond V, Lebbadi M, Salem NJr, Bennett DA, Calon F. 2009. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68: 48-58.
25. Lea PMt, Faden AI. 2003. Modulation of metabotropic glutamate receptors as potential treatment for acute and chronic neurodegenerative disorders. Drug News Perspect 16: 513-522.
26. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y. 2001. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 315(1-2): 61-64.
27. Lipska BK, Halim ND, Segal PN, Weinberger DR. 2002. Effects of reversible inactivation of the neonatal ventral hippocampus on behavior in the adult rat. J Neurosci 22: 2835-2842.
28. Lipska BK, Jaskiw GE, Weinberger DR. 1993. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: A potential animal model of schizophrenia. Neuropsychopharmacology 9: 67-75.
29. Loane DJ, Stoica BA, Pajoohesh-Ganji A, Byrnes KR, Faden AI. 2009. Activation of metabotropic glutamate receptor 5 (mGLUR5) modulates microglial reactivity and neurotoxicity by inhibiting NADPH oxidase. J Biol Chem 284: 15629-15639.
30. Meyer U, Feldon J, Schedlowski M, Yee BK. 2005. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 29: 913-947.
31. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. 2007. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31: 304-307.
32. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. 2008. Minocycline as adjunctive therapy for schizophrenia: An open-label study. Clin Neuropharmacol 31: 287-292.
33. Neugebauer V, Carlton SM. 2002. Peripheral metabotropic glutamate receptors as drug targets for pain relief. Expert Opin Ther Targets 6: 349-361.
34. Parelkar N, Wang J. 2004. mGluR5-dependant increases in immediate early gene expression in the rat striatum following acute administration of amphetamine. Mol Brain Res 122: 151-157.
35. Paxinos G, Watson C. 2005. The Rat Brain in Stereotaxic Coordinates. Academic Press. Amsterdam. 456 p.
36. Seabrook TJ, Jiang L, Maier M, Lemere CA. 2006. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 53: 776-782.
37. Shi L, Fatemi SH, Sidwell RW, Patterson PH. 2003. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 23: 297-302.
38. Shigemoto R, Mizuno N. 2000. Metabotropic glutamate receptors - immunocytochemical and in situ hybridization analyses. In: Ottersen OP, Storm-Mathisen J, editors. Handbook of Chemical Neuroanatomy: Glutamate. Amsterdam: Elsevier Science BV.18. pp 63-98.
39. Slomianka L, West MJ. 2005. Estimators of the precision of stereological estimates: An example based on the CA1 pyramidal cell layer of rats. Neuroscience 136: 757-767.
40. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. 2005. Minocycline as a neuroprotective agent. Neuroscientist 11: 308-322.
41. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. 2001. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21: 2580-2588.
42. Tikka TM, Koistinaho JE. 2001. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 166: 7527-7533.
43. Tilleux S, Berger J, Hermans E. 2007. Induction of astrogliosis by activated microglia is associated with a down-regulation of metabotropic glutamate receptor 5. J Neuroimmunol 189(1-2): 23-30.
44. Tseng KY, Chambers RA, Lipska BK. 2008. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res 204: 295-305.
45. Uno H, Eisele S, Sakai A, Shelton S, Baker E, DeJesus O, Holden J. 1994. Neurotoxicity of glucocorticoids in the primate brain. Horm Behav 28: 336-348.
46. Wang JQ, Tueckmantel W, Zhu A, Pellegrino D, Brownell AL. 2007. Synthesis and preliminary biological evaluation of 3-[(18)F]fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5. Synapse 61: 951-961.
47. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771.
48. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, Tsai CH. 2004. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 350: 1304-1313.
49. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. 1999. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96: 13496-13500.